Barrington Research Weighs in on Surmodics FY2025 Earnings

Surmodics, Inc. (NASDAQ:SRDX) – Equities researchers at Barrington Research lifted their FY2025 EPS estimates for Surmodics in a research report issued on Thursday, November 7th. Barrington Research analyst M. Petusky now forecasts that the company will post earnings of $0.21 per share for the year, up from their prior forecast of $0.19. The consensus estimate for Surmodics’ current full-year earnings is $0.16 per share. Barrington Research also issued estimates for Surmodics’ Q4 2025 earnings at $0.17 EPS.

A number of other brokerages have also recently issued reports on SRDX. StockNews.com initiated coverage on Surmodics in a research report on Thursday. They issued a “hold” rating for the company. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a report on Thursday. Five analysts have rated the stock with a hold rating, According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $50.00.

Surmodics Stock Performance

Shares of SRDX stock opened at $38.46 on Friday. The stock’s 50-day moving average is $38.57 and its two-hundred day moving average is $38.77. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.22 and a current ratio of 3.98. Surmodics has a 1 year low of $25.17 and a 1 year high of $42.44. The firm has a market cap of $548.82 million, a price-to-earnings ratio of -47.48 and a beta of 1.20.

Institutional Trading of Surmodics

Several hedge funds have recently modified their holdings of SRDX. Acadian Asset Management LLC boosted its holdings in Surmodics by 11.3% during the first quarter. Acadian Asset Management LLC now owns 408,779 shares of the company’s stock worth $11,988,000 after buying an additional 41,617 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Surmodics by 5.0% in the 2nd quarter. Renaissance Technologies LLC now owns 606,538 shares of the company’s stock valued at $25,499,000 after buying an additional 28,990 shares in the last quarter. Gardner Lewis Asset Management L P acquired a new stake in Surmodics during the 2nd quarter valued at $8,531,000. Sagefield Capital LP purchased a new position in Surmodics during the second quarter worth $2,350,000. Finally, Trium Capital LLP acquired a new position in shares of Surmodics in the second quarter worth $1,406,000. 96.63% of the stock is owned by institutional investors and hedge funds.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).